insights_auto
Proč je 2269 níž 2,95%?
Prozkoumat hloubějichevron_right
2269:HKG
WuXi Biologics (Cayman) Inc
49,74 HK$
arrow_downward
-2,95%(-1,51) 1D
14. 10., 16:08:24 GMT+8 · HKD
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro 2269…
Otevřít
50,60 HK$
Max.
51,35 HK$
Min.
49,40 HK$
Trž. kap.
204,77 mld.
Prům. obj.
30,95 mil.
Objem
25,22 mil.
Ukazatel P/E
35,58
52týd. max.
58,00 HK$
52týd. min.
28,48 HK$
EPS
1,40 HK$
Akcie v oběhu
1,23 mld.
Počet zaměstnanců
15 tis.
Otevřít
50,60 HK$
Max.
51,35 HK$
Min.
49,40 HK$
Trž. kap.
204,77 mld.
Prům. obj.
30,95 mil.
Objem
25,22 mil.
Ukazatel P/E
35,58
52týd. max.
58,00 HK$
52týd. min.
28,48 HK$
EPS
1,40 HK$
Akcie v oběhu
1,23 mld.
Počet zaměstnanců
15 tis.
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
Stock Titan
·
před 11 minutami
Two governance gaps trigger a Nasdaq notice for Better Home & Finance (NASDAQ: BETR)
MarketWatch
·
před 6 minutami
Why Dell’s stock was one of the S&P 500’s biggest laggards on Wednesday
TradingView
·
před 27 minutami
Taoping Inc. (TAOP) Receives Nasdaq Bid-Price Deficiency Notice
Seeking Alpha
·
před 2 hodinami
Nasdaq tumbles 2%, and these 10 stocks have fueled the selloff
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Informace o WuXi Biologics (Cayman) Inc